439 related articles for article (PubMed ID: 29908325)
21. Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice.
Volta M; Beccano-Kelly DA; Paschall SA; Cataldi S; MacIsaac SE; Kuhlmann N; Kadgien CA; Tatarnikov I; Fox J; Khinda J; Mitchell E; Bergeron S; Melrose H; Farrer MJ; Milnerwood AJ
Elife; 2017 Sep; 6():. PubMed ID: 28930069
[TBL] [Abstract][Full Text] [Related]
22. Dopamine D2 receptor desensitization by dopamine or corticotropin releasing factor in ventral tegmental area neurons is associated with increased glutamate release.
Nimitvilai S; Herman M; You C; Arora DS; McElvain MA; Roberto M; Brodie MS
Neuropharmacology; 2014 Jul; 82():28-40. PubMed ID: 24657149
[TBL] [Abstract][Full Text] [Related]
23. R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations.
Xenias HS; Chen C; Kang S; Cherian S; Situ X; Shanmugasundaram B; Liu G; Scesa G; Savio Chan C; Parisiadou L
Commun Biol; 2022 Nov; 5(1):1211. PubMed ID: 36357506
[TBL] [Abstract][Full Text] [Related]
24. Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging.
Longo F; Russo I; Shimshek DR; Greggio E; Morari M
Neurobiol Dis; 2014 Nov; 71():62-73. PubMed ID: 25107341
[TBL] [Abstract][Full Text] [Related]
25. Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.
Alvarsson A; Zhang X; Stan TL; Schintu N; Kadkhodaei B; Millan MJ; Perlmann T; Svenningsson P
J Neurosci; 2015 Oct; 35(41):14057-69. PubMed ID: 26468205
[TBL] [Abstract][Full Text] [Related]
26. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
[TBL] [Abstract][Full Text] [Related]
27. Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids.
André VM; Cepeda C; Cummings DM; Jocoy EL; Fisher YE; William Yang X; Levine MS
Eur J Neurosci; 2010 Jan; 31(1):14-28. PubMed ID: 20092552
[TBL] [Abstract][Full Text] [Related]
28. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
29. Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
Sciaccaluga M; Mazzocchetti P; Bastioli G; Ghiglieri V; Cardinale A; Mosci P; Caccia C; Keywood C; Melloni E; Padoani G; Vailati S; Picconi B; Calabresi P; Tozzi A
Neuropharmacology; 2020 Jun; 170():108024. PubMed ID: 32142791
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology.
Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL
eNeuro; 2017; 4(2):. PubMed ID: 28321439
[TBL] [Abstract][Full Text] [Related]
31. G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice.
Arbez N; He X; Huang Y; Ren M; Liang Y; Nucifora FC; Wang X; Pei Z; Tessarolo L; Smith WW; Ross CA
Hum Mol Genet; 2020 Mar; 29(4):580-590. PubMed ID: 31813996
[TBL] [Abstract][Full Text] [Related]
32. The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.
Sweet ES; Saunier-Rebori B; Yue Z; Blitzer RD
J Neurosci; 2015 Aug; 35(32):11190-5. PubMed ID: 26269629
[TBL] [Abstract][Full Text] [Related]
33. In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity.
Novello S; Mercatelli D; Albanese F; Domenicale C; Brugnoli A; D'Aversa E; Vantaggiato S; Dovero S; Murtaj V; Presotto L; Borgatti M; Shimshek DR; Bezard E; Moresco RM; Belloli S; Morari M
Neurobiol Dis; 2022 Jan; 162():105579. PubMed ID: 34871735
[TBL] [Abstract][Full Text] [Related]
34. Reduced striatal dopamine DA D2 receptor function in dominant-negative GSK-3 transgenic mice.
Gomez-Sintes R; Bortolozzi A; Artigas F; Lucas JJ
Eur Neuropsychopharmacol; 2014 Sep; 24(9):1524-33. PubMed ID: 25088904
[TBL] [Abstract][Full Text] [Related]
35. LRRK2 mutation alters behavioral, synaptic, and nonsynaptic adaptations to acute social stress.
Guevara CA; Matikainen-Ankney BA; Kezunovic N; LeClair K; Conway AP; Menard C; Flanigan ME; Pfau M; Russo SJ; Benson DL; Huntley GW
J Neurophysiol; 2020 Jun; 123(6):2382-2389. PubMed ID: 32374202
[TBL] [Abstract][Full Text] [Related]
36. Leucine-rich repeat kinase 2 phosphorylation on synapsin I regulates glutamate release at pre-synaptic sites.
Marte A; Russo I; Rebosio C; Valente P; Belluzzi E; Pischedda F; Montani C; Lavarello C; Petretto A; Fedele E; Baldelli P; Benfenati F; Piccoli G; Greggio E; Onofri F
J Neurochem; 2019 Aug; 150(3):264-281. PubMed ID: 31148170
[TBL] [Abstract][Full Text] [Related]
37. G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice.
Novello S; Arcuri L; Dovero S; Dutheil N; Shimshek DR; Bezard E; Morari M
Neurobiol Dis; 2018 Dec; 120():21-33. PubMed ID: 30172844
[TBL] [Abstract][Full Text] [Related]
38. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
[TBL] [Abstract][Full Text] [Related]
39. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.
Yue M; Hinkle KM; Davies P; Trushina E; Fiesel FC; Christenson TA; Schroeder AS; Zhang L; Bowles E; Behrouz B; Lincoln SJ; Beevers JE; Milnerwood AJ; Kurti A; McLean PJ; Fryer JD; Springer W; Dickson DW; Farrer MJ; Melrose HL
Neurobiol Dis; 2015 Jun; 78():172-95. PubMed ID: 25836420
[TBL] [Abstract][Full Text] [Related]
40. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
